Next Science Ltd ( (AU:NXS) ) has provided an update.
Next Science Limited will release its first-quarter financial results for FY25 on April 24, 2025, followed by an investor webinar hosted by CEO I.V. Hall and CFO Marc Zimmerman. This announcement is part of the company’s ongoing efforts to engage with the investment community and provide transparency about its financial performance. The results and subsequent discussion could impact stakeholders’ perceptions and the company’s market positioning, particularly given its focus on innovative medical technology solutions.
More about Next Science Ltd
Next Science is a medical technology company based in Sydney, Australia, with a research and development center in Florida, USA. Founded in 2012, the company specializes in developing and commercializing its proprietary XBIO™ technology, which is designed to combat biofilm-based infections in human health. The technology is non-toxic and effective against both biofilm-based and free-floating bacteria, and Next Science holds full patent rights to this intellectual property.
YTD Price Performance: -28.57%
Average Trading Volume: 5,955
Technical Sentiment Signal: Strong Buy
Current Market Cap: $18.8M
See more data about NXS stock on TipRanks’ Stock Analysis page.